Vitrafy Life Sciences Limited provides cryopreservation solutions in Australia. Its cryopreservation technology improves the cell survival of cryopreserved biological materials, such as blood platelets used to treat trauma patients, t cells used in cancer treatments, and animal sperm used in breeding and farming. The company provides smart freezing device, smart thawing device, and LifeChain, a sample quality management software platform, as well as smart blood bag and sperm packaging solution. It serves animal genetics and animal reproduction suppliers; blood platelets organizations, biobanks, and points of care; and human cell and gene therapies markets. The company has research and collaboration agreement with CSL Innovation Pty Ltd, US Army Institute of Surgical Research, Select Sires, Inc. and a Huon Aquaculture Company Pty Ltd. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.
Metrics to compare | VFY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVFYPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.1x | −0.9x | −0.5x | |
PEG Ratio | −0.04 | 0.00 | 0.00 | |
Price/Book | 3.6x | 1.4x | 2.6x | |
Price / LTM Sales | 97.5x | 3.6x | 3.3x | |
Upside (Analyst Target) | 31.7% | 114.1% | 43.5% | |
Fair Value Upside | Unlock | 14.2% | 6.9% | Unlock |